Literature DB >> 26604134

MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes.

Manuel Comabella1, Ester Cantó2, Ramil Nurtdinov2, Jordi Río2, Luisa M Villar3, Carmen Picón3, Joaquín Castilló2, Nicolás Fissolo2, Xavier Aymerich4, Cristina Auger4, Alex Rovira4, Xavier Montalban2.   

Abstract

Little is known about the mechanisms leading to neurodegeneration in multiple sclerosis (MS) and the role of peripheral blood cells in this neurodegenerative component. We aimed to correlate brain radiological phenotypes defined by high and low neurodegeneration with gene expression profiling of peripheral blood mononuclear cells (PBMC) from MS patients. Magnetic resonance imaging (MRI) scans from 64 patients with relapsing-remitting MS (RRMS) were classified into radiological phenotypes characterized by low (N = 27) and high (N = 37) neurodegeneration according to the number of contrast-enhancing lesions, the relative volume of non-enhancing black holes on T1-weighted images, and the brain parenchymal fraction. Gene expression profiling was determined in PBMC using microarrays, and validation of selected genes was performed by polymerase chain reaction (PCR). B-cell immunophenotyping was conducted by flow cytometry. Microarray analysis revealed the B-cell specific genes FCRL1, FCRL2, FCRL5 (Fc receptor-like 1, 2 and 5 respectively), and CD22 as the top differentially expressed genes between patients with high and low neurodegeneration. Levels for these genes were significantly down-regulated in PBMC from patients with MRI phenotypes characterized by high neurodegeneration and microarray findings were validated by PCR. In patients with high neurodegeneration, immunophenotyping showed a significant increase in the expression of the B-cell activation markers CD80 in naïve B cells (CD45+/CD19+/CD27-/IgD+), unswitched memory B cells (CD45+/CD19+/CD27+/IgD+), and switched memory B cells (CD45+/CD19+/CD27+/IgD-), and CD86 in naïve and switched memory B cells. These results suggest that RRMS patients with radiological phenotypes showing high neurodegeneration have changes in B cells characterized by down-regulation of B-cell-specific genes and increased activation status.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26604134     DOI: 10.1093/hmg/ddv473

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  12 in total

1.  Potential Biomarker and Therapeutic LncRNAs in Multiple Sclerosis Through Targeting Memory B Cells.

Authors:  Elahe Ghoveud; Shohreh Teimuri; Jafar Vatandoost; Aref Hosseini; Kamran Ghaedi; Masood Etemadifar; Mohammad Hossein Nasr Esfahani; Timothy L Megraw
Journal:  Neuromolecular Med       Date:  2019-10-01       Impact factor: 3.843

2.  Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells.

Authors:  Ide Smets; Barnaby Fiddes; Josselyn E Garcia-Perez; Di He; Klara Mallants; Wenjia Liao; James Dooley; George Wang; Stephanie Humblet-Baron; Bénédicte Dubois; Alastair Compston; Joanne Jones; Alasdair Coles; Adrian Liston; Maria Ban; An Goris; Stephen Sawcer
Journal:  Brain       Date:  2018-03-01       Impact factor: 13.501

Review 3.  Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.

Authors:  David Baker; Monica Marta; Gareth Pryce; Gavin Giovannoni; Klaus Schmierer
Journal:  EBioMedicine       Date:  2017-01-31       Impact factor: 8.143

4.  Changes in expression profiles of internal jugular vein wall and plasma protein levels in multiple sclerosis.

Authors:  Giovanna Marchetti; Nicole Ziliotto; Silvia Meneghetti; Marcello Baroni; Barbara Lunghi; Erica Menegatti; Massimo Pedriali; Fabrizio Salvi; Ilaria Bartolomei; Sofia Straudi; Fabio Manfredini; Rebecca Voltan; Nino Basaglia; Francesco Mascoli; Paolo Zamboni; Francesco Bernardi
Journal:  Mol Med       Date:  2018-08-09       Impact factor: 6.354

5.  Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study.

Authors:  Irene Moreno-Torres; Coral González-García; Marco Marconi; Aranzazu García-Grande; Luis Rodríguez-Esparragoza; Víctor Elvira; Elvira Ramil; Lucía Campos-Ruíz; Ruth García-Hernández; Fátima Al-Shahrour; Coral Fustero-Torre; Alicia Sánchez-Sanz; Antonio García-Merino; Antonio José Sánchez López
Journal:  Front Immunol       Date:  2018-07-25       Impact factor: 7.561

6.  Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study.

Authors:  Maria Liguori; Nicoletta Nuzziello; Marta Simone; Nicola Amoroso; Rosa Gemma Viterbo; Sabina Tangaro; Arianna Consiglio; Paola Giordano; Roberto Bellotti; Maria Trojano
Journal:  Brain Behav       Date:  2019-01-17       Impact factor: 2.708

7.  MRI phenotypes in MS: Longitudinal changes and miRNA signatures.

Authors:  Christopher C Hemond; Brian C Healy; Shahamat Tauhid; Maria A Mazzola; Francisco J Quintana; Roopali Gandhi; Howard L Weiner; Rohit Bakshi
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-02-14

Review 8.  B cells in autoimmune and neurodegenerative central nervous system diseases.

Authors:  Joseph J Sabatino; Anne-Katrin Pröbstel; Scott S Zamvil
Journal:  Nat Rev Neurosci       Date:  2019-11-11       Impact factor: 34.870

Review 9.  The Role of B Cells in Primary Progressive Multiple Sclerosis.

Authors:  Jameson P Holloman; Robert C Axtell; Nancy L Monson; Gregory F Wu
Journal:  Front Neurol       Date:  2021-06-07       Impact factor: 4.086

Review 10.  An Overview of the Intrinsic Role of Citrullination in Autoimmune Disorders.

Authors:  Mohammed Alghamdi; Doaa Alasmari; Amjad Assiri; Ehab Mattar; Abdullah A Aljaddawi; Sana G Alattas; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2019-11-25       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.